GRCE

Grace Therapeutics, Inc. Common Stock

3.45 USD
-0.03
0.86%
At close Feb 14, 4:00 PM EST
1 day
-0.86%
5 days
4.86%
1 month
-1.43%
3 months
4.23%
6 months
42.56%
Year to date
-13.75%
1 year
30.68%
5 years
-87.39%
10 years
-98.40%
 

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Employees: 4

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

1% more capital invested

Capital invested by funds: $6.31M [Q2] → $6.36M (+$57.2K) [Q3]

0% more funds holding

Funds holding: 12 [Q2] → 12 (+0) [Q3]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Research analyst outlook

We haven’t received any recent analyst ratings for GRCE.

Financial journalist opinion

Based on 4 articles about GRCE published over the past 30 days

Neutral
GlobeNewsWire
3 days ago
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced financial results and business highlights for the quarter ended December 31, 2024.
Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Positive
Benzinga
6 days ago
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
On Monday, Grace Therapeutics, Inc. GRCE, formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH).
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
Neutral
GlobeNewsWire
6 days ago
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Neutral
GlobeNewsWire
6 days ago
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal Subarachnoid Hemorrhage (aSAH) patients, today announced that its Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) met its primary endpoint and provides evidence of clinical benefit when compared to orally administered nimodipine.
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Neutral
GlobeNewsWire
1 month ago
Grace Therapeutics to Participate in Upcoming Investor Events January 2025
PRINCETON, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Nasdaq: ACST) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs, today announced that Chief Executive Officer Prashant Kohli will participate the following investor and industry networking events during the month of January 2025.
Grace Therapeutics to Participate in Upcoming Investor Events January 2025
Charts implemented using Lightweight Charts™